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Stroke survivors are at increased risk of recurrent ischemic events, including recurrent stroke and myocardial infarc-
tion (MI).1 Particularly in the first hours and days after a tran-
sient ischemic attack (TIA) or stroke, risk of recurrence is high.2,3 
Recurrent strokes lead to dementia more often and have higher 
case fatality than first strokes.4 Antiplatelet therapy is a corner-
stone in secondary prevention and successfully reduces the 
frequency of vascular events5; for patients with noncardioembolic 
stroke or TIA the relative risk reduction of aspirin was 13%.6
Guidelines vary, but most recommend aspirin, aspirin/di-
pyridamole combination or clopidogrel as first-line treatment 
in long-term secondary prevention after noncardioembolic 
stroke or TIA.7,8 Given the mixed evidence and important 
differences between various antiplatelet agents, it becomes 
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challenging for clinicians to select an optimal agent for an in-
dividual patient.
A few network meta-analyses (NMA) have been per-
formed to compare the long-term efficacy of antiplatelet 
therapies among patients with stroke or TIA9–13; however, 
these analyses were performed on aggregated data from ran-
domized controlled trials that included patients with different 
underlying causes of ischemic stroke/TIA. As a result, these 
analyses could not adequately restrict their study population 
to patients with noncardioembolic stroke or TIA, while appro-
priate use of antiplatelet drugs after TIA or ischemic stroke 
depends on whether the underlying cause is cardioembolic or 
not. Furthermore, these analyses based on published, aggre-
gate data could not deal with differences in reported outcome 
definitions (eg, vascular death including or excluding hemor-
rhagic deaths from any origin). Also, not all trials reported 
the results of intracranial hemorrhage or major bleeding, thus 
some comparisons between antiplatelet therapies for safety 
outcomes were lacking. In addition, individual trials are usu-
ally not powered for subgroup analyses, and meta-analyses 
using published aggregate data on subgroups have substan-
tial limitations because of the inability to systematically ad-
just for potential confounders. A pooled individual participant 
data analytic approach is most suitable for assessing subgroup 
effects with sufficient power and adequate adjustment for po-
tential confounders.14
Therefore, we performed an individual patient data net-
work meta-analysis (IPD-NMA) to compare the efficacy and 
safety of antiplatelet therapies frequently used for long-term 
secondary stroke prevention in patients with noncardioem-
bolic stroke or TIA and among patient subgroups.
Methods
Data Availability
Requests for access to data from the Cerebrovascular Antiplatelet 
Trialists’ database will be considered by the Cerebrovascular 
Antiplatelet Trialists’ Steering Committee.
Study Population
A detailed description of the design of the IPD-NMA has been 
described elsewhere.15 Briefly, we obtained data for patients from 
trials investigating the efficacy of antiplatelet therapy in long-term 
secondary prevention after a TIA or ischemic stroke. Trials were 
eligible if they randomized patients with TIA or ischemic stroke to 
antiplatelet regimens (monotherapy or dual therapy) for long-term 
secondary prevention after stroke. Because homogeneity and con-
sistency assumptions underlie NMA,16 we did not include RCTs 
assessing aspirin versus placebo because such studies had a wide 
range of daily doses (75–1500 mg). Although the benefit of aspirin 
is quite consistent at low, medium, and high doses of aspirin,6 side 
effects appear to be dose-related. Another reason for excluding 
these RCTs is that the evaluation of antiplatelet therapy versus 
placebo has become less clinically important. We also excluded 
randomized studies of short-duration (<3 months), those that only 
assessed surrogate outcomes, or those that specifically focused 
on patients with lacunar infarcts. Studies that examined triflusal, 
cilostazol, terutroban, ticlopidine, or dipyridamole alone were also 
excluded, as our interest was to evaluate the efficacy and safety of 
commonly prescribed antiplatelet regimens in patients with noncar-
dioembolic ischemic stroke or TIA. We used the methods described 
in the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses statement.
Data Extraction
For all eligible trials, we sought to obtain individual patient data. Data 
were obtained on the following baseline variables: demographics 
(age, sex, and ethnicity), smoking, medical history (hypertension, hy-
percholesterolemia, diabetes mellitus, history of stroke or TIA, his-
tory of cardiovascular disease, and history of heart failure), clinical 
presentation (nature of qualifying event [TIA versus minor ischemic 
stroke], type of vessel involved [small vessel disease versus large ves-
sel disease] time from event to randomization, and severity of stroke 
at entry), and randomized treatment allocation (aspirin, clopidogrel, 
aspirin/dipyridamole combination, and aspirin/clopidogrel combina-
tion). Data were also obtained on the nature and timing of the fol-
lowing outcome variables: any recurrent stroke, recurrent ischemic 
stroke, MI, major bleeding, intracranial bleeding, and cause of any 
deaths. All data were merged into a single composite database, the 
Cerebrovascular Antiplatelet Trialists’ database. Detailed consider-
ation was given to the definitions of baseline variables used in the 
original trials. When definitions were identical, comparable data were 
merged. If possible, differences in definitions of baseline variables 
between studies were resolved by reconstruction of definitions to 
achieve comparability. We excluded patients with a possible cardio-
embolic origin of their TIA or stroke (those with a history of atrial fi-
brillation or Trial of ORG 10172 in Acute Stroke Treatment [TOAST] 
classification cardioembolic stroke).
Redefinition of Outcome Events
Detailed consideration was given to the outcome definitions used in 
the original trial reports.
We accepted the reported definitions of ischemic stroke, intra-
cranial hemorrhage (including intracerebral hemorrhage, subarach-
noid hemorrhage, and epidural and subdural hematomas), all-cause 
mortality, death from nonvascular causes, and MI as defined by the 
trial investigators and did not attempt to retrospectively reclassify 
events.15 Composite outcome definitions of stroke and vascular 
death vary across the trials.15 For the combined analysis, subdural 
and epidural hematomas were counted as intracranial hemorrhages, 
but not as strokes.15 Vascular death includes hemorrhagic deaths 
from any origin.15
The primary efficacy outcomes of interest were serious vascular 
events (defined as the composite of stroke, MI, or vascular death) and 
ischemic events (composite of ischemic stroke, MI, or vascular death 
[excluding hemorrhagic death]). Primary safety outcomes were major 
(including fatal) bleeding and primary intracranial hemorrhage. 
There were minor differences in definition of major bleeding between 
trials,15 but designations made in the original trials were not changed. 
Major bleedings were fatal, intracranial, required hospital admis-
sion, or led to significant disability. Secondary exploratory outcomes 
included net clinical benefit outcome (defined as the composite of 
stroke, MI, vascular death, or major bleeding) and ischemic stroke.
Statistical Analysis
All analyses were by intention to treat based on the randomized 
treatment allocation. For each outcome, we cross-checked indi-
vidual data against previous publications (Table I in the online-only 
Data Supplement). Second, we calculated unadjusted and adjusted 
risk ratios for each outcome within each trial with Poisson regres-
sion with robust SEs. In the adjusted analyses, we account for the 
following prespecified covariates: age, sex, hypertension, diabetes 
mellitus, current smoking, qualifying diagnosis (stroke versus TIA). 
Pooled unadjusted and adjusted risk ratios (RR) were obtained by 
random-effects network meta-analyses with package netmeta in R. 
We estimated ranking probabilities for all antiplatelet regimens of 
being at each possible rank for each treatment. The treatment hier-
archy was summarized and reported as Surface Under the Cumulative 
Ranking Curve, which measures the average probability that a treat-
ment is better than the competing treatments.17 The network results 
were assessed for consistency by comparing them with the results 
from individual trials or pairwise meta-analyses. To investigate the 
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who used treatment (on-treatment analysis), in which we included 
only the outcome events that arose while study treatment was being 
taken or before the 28th day after the discontinuation of treatment.
Third, to determine whether the results were affected by patient 
characteristics, we did subgroup network meta-analyses for the main 
outcomes (serious vascular events and major bleeding) according to 
the following characteristics: sex, age (<65 versus ≥65 years), eth-
nicity (Asian versus non-Asian), hypertension (yes versus no), qualify-
ing diagnosis (stroke versus TIA), type of vessel involved (large versus 
small vessel disease), and time from qualifying event to randomization 
(≤21 days versus >21 days). These variables were selected following a 
review of risk scores, clinical guidelines, trial subgroup analyses, and 
clinical advice.7,8,18–23 All subgroup analyses are reported as adjusted 
effects (adjusted for the same prespecified covariates as in the pri-
mary analyses). Fourth, we performed several sensitivity analyses in 
which we either omitted the MATCH trial, where only patients with 
ischemic stroke/TIA at high vascular risk were included, or omitted 
the CHARISMA trial, where patients with previous symptomatic ce-
rebrovascular disease within the previous 5 years were included, or 
omitted the ESPRIT trial in which an open, nonblinded study design 
was used. We did analyses with IBM SPSS Statistics (version 23), 
Review Manager (version 5.3), and R (version 3.3.1).
Results
Six trials (CAPRIE, ESPS-2, MATCH, CHARISMA, ESPRIT, 
and PRoFESS19–24) met the inclusion criteria, including 48 023 
patients with a TIA or ischemic stroke recruited between 
1989 and 2006. Table II in the online-only Data Supplement 
presents the main characteristics of the 6 trials. After exclu-
sion of patients randomized to placebo or dipyridamole alone 
(n=3303) and patients with a possible cardioembolic origin of 
their stroke (n=1608), 43 112 patients remained for the analy-
ses. The antiplatelet treatment comparisons are visualized in a 
network (Figure 1). Detailed results of the individual trials and 
pairwise meta-analyses are given in Table I in the online-only 
Data Supplement.
Patient characteristics stratified by trial arm are presented 
in Table 1. The median time to randomization was 21 days 
(range, 15–124) and patients were followed for a median of 
2.0 years (1.5–3.5). Mean age was 65±10 years and 36% were 
female. Ninety percent had a stroke as qualifying event and 
small vessel disease was diagnosed in 50% of the patients. 
Patient characteristics were similar between treatment options, 
except for a greater proportion of patients with vascular risk 
factors in patients treated with clopidogrel monotherapy or 
the aspirin/clopidogrel combination, and a greater propor-
tion of patients with large vessel disease in patients treated 
with aspirin monotherapy. In terms of study quality, all 6 trials 
were rated as low risk of bias studies (Figure I in the online-
only Data Supplement).
Serious Vascular Events
A total of 5424 (12.6%) serious vascular events and 5022 
(11.6%) ischemic events occurred. The adjusted NMA treat-
ment effects are reported in Table 2. The results are con-
sistent with the unadjusted NMA results, the results from 
individual trials or pairwise meta-analyses and the on-treat-
ment analyses (Tables I, III, and IV in the online-only Data 
Supplement). Aspirin/dipyridamole combination significantly 
reduced the risk of serious vascular events compared with as-
pirin (RR
NMA-adj
, 0.83; 95% CI, 0.74–0.94), as did clopidogrel 
(RR
NMA-adj
, 0.88; 95% CI, 0.78–0.98), and aspirin/clopidogrel 
combination (RR
NMA-adj
, 0.83; 95% CI, 0.71–0.96). There were 
no statistically significant differences with respect to the occur-
rence of serious vascular event risks between patients taking 
clopidogrel, aspirin/dipyridamole combination, or aspirin/
clopidogrel combination. Similarly, clopidogrel, aspirin/di-
pyridamole combination, and aspirin/clopidogrel combination 
significantly reduced the risk of ischemic events compared 
with aspirin (RRs range, 0.83–0.91); aspirin/dipyridamole 
combination and aspirin/clopidogrel combination significantly 
reduced the risk of ischemic stroke compared with aspirin.
Major Bleeding Events
In terms of safety, 1530 (3.5%) major bleedings and 380 
(0.9%) intracranial hemorrhages occurred. Clopidogrel 
caused significantly less major bleeding (RR
NMA-adj
, 0.76; 
95% CI, 0.63–0.91) and intracranial hemorrhage (RR
NMA-adj
, 
0.63; 95% CI, 0.43–0.91) than aspirin. Aspirin/dipyrida-
mole combination caused significantly more major bleeding 
(RR
NMA-adj
, 1.14; 95% CI, 1.00–1.30) and intracranial hemor-
rhage (RR
NMA-adj
, 1.40; 95% CI, 1.08–1.82) than clopidogrel. 
Aspirin/clopidogrel combination caused significantly more 
major bleeding than aspirin, clopidogrel, and aspirin/dipyrid-
amole combination (Table 2).
The net clinical benefit outcome (serious vascular events 
or major bleeding) was similar for clopidogrel and aspirin/di-
pyridamole combination (RR
NMA-adj
, 0.99; 95% CI, 0.93–1.05). 
Risk of this combined outcome was reduced by clopidogrel 
(RR
NMA-adj
, 0.89; 95% CI, 0.82–0.96) and aspirin/dipyridamole 
(RR
NMA-adj
, 0.87; 95% CI, 0.80–0.95) compared with aspirin.
Sensitivity Analysis and Ranking
All results were similar after exclusion of 7252 (17%) patients 
with TIA/ischemic stroke at high vascular risk in MATCH, 
after exclusion of 4240 (10%) patients in CHARISMA who 
had symptomatic cerebrovascular disease within the previous 
5 years, or after exclusion of 2739 (6%) patients randomized 
in ESPRIT in which an open, nonblinded study design was 
used (Table V in the online-only Data Supplement). The rank-
ing of treatments based on cumulative probability (Surface 
Under the Cumulative Ranking Curve) is presented in Table 
VI in the online-only Data Supplement. In terms of efficacy, 
the most effective treatments were aspirin/clopidogrel combi-
nation and aspirin/ dipyridamole combination. Both treatments 
Figure 1. Network of randomized controlled trial evidence. Ellipses rep-
resent comparators. Arrows represent comparisons of interventions for 
which trial data were available. Patient numbers represent the total number 
of patients enrolled in each trial informing the comparison of interest. ASA 
indicates aspirin; ASACLO, aspirin/clopidogrel combination; ASADIP, as-
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have a probability around 75% of being superior to a competing 
treatment. Clopidogrel has the highest probability of being the 
best treatment modality in terms of safety (99%), followed by 
aspirin/dipyridamole combination (65%). Combining the rank-
ings for efficacy and safety indicates that both clopidogrel and 
aspirin/dipyridamole combination seemed to be best choices, 
because both had a favorable balance between efficacy and 
safety (Figure 2; Table VI in the online-only Data Supplement).
Subgroup Analyses
We also investigated whether the treatment effect differed be-
tween certain subgroups of patients (Table VII in the online-
only Data Supplement). For serious vascular events, there was 
no evidence of heterogeneity of treatment effect across any 
of the prespecified subgroups. Excess risks of major bleeding 
were similar for most of the subgroups, apart from patient age. 
Aspirin/clopidogrel combination showed more major bleed-
ing complications than clopidogrel, especially in younger 
patients. The adjusted excess risk for major bleeding varied 
from 1.7× higher (RR
NMA-adj
, 1.7; 95% CI, 1.3–2.2) in patients 
aged ≥65 years to a ≈4-fold excess risk (RR
NMA-adj
, 3.9; 95% 
CI, 2.5–6.0) in patients aged <65 years.
This subgroup effect was already apparent in the MATCH 
trial: patients older than 65 years assigned to aspirin/clopido-
grel had a 1.6× increased risk of major bleeding (92 [3.0%/y] 
of 2169 patients versus 54 [1.8%/y] of 2097 assigned to clopi-
dogrel; RR
adj
, 1.6; 95% CI, 1.2–2.3). Patients younger than 65 
years assigned to aspirin/clopidogrel had a 4-fold increased 
risk of major bleeding (67 [3.2%/y] of 1466 patients versus 
16 [0.7%/y] of 1520 assigned to clopidogrel; RR
adj
, 4·3; 95% 
CI, 2.5–7.5).
Discussion
Our collaborative IPD-NMA indicates that clopidogrel and as-
pirin/dipyridamole combination both showed a favorable bal-
ance between efficacy and safety. Benefits were seen across a 
wide range of subgroups.
Long-term combination of clopidogrel and aspirin resulted 
in significantly more major bleeding complications compared 
with aspirin or clopidogrel alone, doubling the number of 
Table 1. Baseline Characteristics of Patients Included in the Trials
ASA CLO ASADIP ASACLO
n=8127 n=16 519 n=12 712 n=5754
Demographic characteristics
  Age (mean±SD) 65 11 66 9 66 9 66 10
  Female sex 3011 37% 5968 36% 4591 36% 2139 37%
  Asian ethnicity 420 5% 3415 21% 3454 27% 306 5%
Qualifying event characteristics
  Ischemic stroke type 6756 83% 15 737 95% 11 851 93% 4471 78%
  Moderately severe disability (modified 
Rankin Scale score of 3–5)*
1113 22% 3720 24% 2724 23% 752 26%
  Lacunar stroke subtype† 2567 43% 7940 51% 6559 52% 1557 54%
  Median time from qualifying event to 
randomization, d
41  18  17  24  
  <7 d 697 9% 2797 17% 2477 20% 944 16%
  7 d to 1 mo (30 d) 2777 34% 7853 48% 5642 44% 2193 38%
  ≥1 mo 4645 57% 5835 35% 4571 36% 2617 45%
Risk factors and medical history
  Current smoking 2025 25% 3459 21% 3018 24% 1073 19%
  Hypertension 5097 63% 12 051 73% 8790 69% 4447 77%
  Hypercholesterolemia 3354 41% 7857 48% 5530 44% 3301 57%
  Diabetes mellitus 1901 23% 6036 37% 3325 26% 3111 54%
  Heart failure 266 4% 623 4% 309 3% 328 6%
  Myocardial infarction 742 9% 1167 7% 861 7% 316 5%
  Previous stroke‡ 1020 13% 3248 20% 1972 16% 1158 20%
  Previous TIA‡ 977 15% 2027 12% 1026 9% 993 17%
ASA indicates aspirin; ASACLO, aspirin/clopidogrel combination; ASADIP, aspirin/dipyridamole combination; CLO, clopidogrel; and TIA, transient 
ischemic attack.
*For patients randomized after an ischemic stroke only, data not collected in CHARISMA.
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events. Also, older age was positively associated with higher 
bleeding risks for all antiplatelet regimens. However, major 
bleeding risk did not further increase in older patients on 
the aspirin/clopidogrel combination compared with younger 
patients, indicating a risk ceiling effect of ≈3% per year. This 
effect is likely to be related to the fact that patients with high 
bleeding risks were not included in the trials, due to strict ex-
clusion criteria or that their bleeding led to premature death. 
The unexpected effect of age on treatment effect observed by 
pooling these trials was present in the MATCH trial, but has 
not been reported. Our findings suggest that future trials of new 
antiplatelet regimens in long-term stroke prevention should 
examine risk of bleeding for younger and older patients sepa-
rately. Also, coprescription of a proton-pump inhibitor could be 
considered in future studies, as has been suggested recently.25
To date, several network meta-analyses have been con-
ducted to assess the effects of different antiplatelet regimens in 
the secondary stroke prevention.9–13 One NMA showed that the 
aspirin/dipyridamole combination was better than using clopi-
dogrel or aspirin alone in the secondary prevention of serious 
vascular events after TIA or ischemic stroke10; this finding was 
not consistent with our analysis. We consider the main reason 
to be that results of the PRoFESS trial, which showed similar 
rates of recurrent stroke in patients receiving aspirin/dipyrida-
mole combination and in patients receiving clopidogrel, were 
published after this review. In another NMA, Malloy et al11 
reported that more bleeding events seemed to occur with the 
combination of aspirin and clopidogrel than with other treat-
ments, and our results are in line with that finding. Two recent 
network analyses have shown that cilostazol had the best risk-
benefit profile for long-term secondary prevention after stroke 
or TIA.12,13 We excluded trials that assessed cilostazol, since 
all trials that investigated the effect of cilostazol in the long-
term secondary stroke prevention were performed in patients 
of Asian descent26–28; therefore the effect of cilostazol may not 
be generalizable to non-Asian populations. More randomized 
controlled trials in non-Asian patients are needed to determine 
whether the use of cilostazol is a good option for long-term 
secondary stroke prevention. Other conventional pairwise 
meta-analyses focused on the effect of short-term and long-
term dual antiplatelet therapy compared with monotherapy.29,30 
However, antiplatelet agents used in dual and single antiplate-
let therapies varied across trials.
Analysis of individual patient data has advantages over 
meta-analysis of overall trial results. The availability of indi-
vidual data for a large number of patients enabled us to make 
a more precise assessment of the relative treatment effects 
of antiplatelet agents than has been possible previously. One 
of the strengths of our study is the standardized definition of 
composite outcomes. Differences between the trials in the def-
inition of composite outcomes made it previously impossible 
Table 2. Adjusted Treatment Effect Estimates From Network Meta-Analysis for Efficacy and Safety
Serious Vascular 
Event Ischemic Event Ischemic Stroke Major Bleeding
Intracranial 
Hemorrhage




 (95% CI) RR
adj
 (95% CI) RR
adj
 (95% CI) RR
adj
 (95% CI) RR
adj




  Clopidogrel 0.88 (0.78–0.98) 0.91 (0.83–0.99) 0.91 (0.81–1.02) 0.76 (0.63–0.91) 0.63 (0.43–0.91) 0.89 (0.82–0.96)
  Aspirin+dipyridamole 0.83 (0.74–0.94) 0.86 (0.78–0.95) 0.86 (0.76–0.97) 0.86 (0.71–1.05) 0.88 (0.60–1.31) 0.87 (0.80–0.95)
  Aspirin+clopidogrel 0.83 (0.71–0.96) 0.83 (0.73–0.94) 0.83 (0.71–0.97) 1.63 (1.29–2.07) 1.19 (0.68–2.08) 0.94 (0.84–1.05)
Compared with clopidogrel
  Aspirin+dipyridamole 0.95 (0.85–1.06) 0.95 (0.89–1.02) 0.95 (0.87–1.04) 1.14 (1.00–1.30) 1.40 (1.08–1.82) 0.99 (0.93–1.05)
  Aspirin+clopidogrel 0.94 (0.82–1.08) 0.91 (0.82–1.02) 0.91 (0.80–1.04) 2.16 (1.72–2.71) 1.88 (1.12–3.16) 1.06 (0.96–1.17)
Compared with aspirin+dipyridamole
  Aspirin+clopidogrel 0.99 (0.84–1.17) 0.96 (0.85–1.09) 0.96 (0.82–1.13) 1.89 (1.47–2.42) 1.34 (0.77–2.36) 1.08 (0.96–1.20)
*The net clinical benefit outcome was the composite of stroke, myocardial infarction, vascular death, or major bleeding. Adjusted (Adj) for age, sex, hypertension, 
diabetes mellitus, current smoking, and qualifying diagnosis (stroke vs transient ischemic attack).
Figure 2. Clustered ranking plot for the outcomes serious vascular events 
and major bleeding. The probabilities of each treatment being ranked best 
in terms of efficacy (serious vascular events) and safety (major bleeding) 
outcomes are represented by their Surface Under the Cumulative Rank-
ing curve (SUCRA) values. Treatments lying in the upper right corner are 
more effective in preventing serious vascular events, with lower propensity 
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to combine reported aggregate results satisfactorily. Also, we 
could study safety outcomes such as major bleeding and intra-
cranial hemorrhage in more detail and could restrict our study 
population to patients with noncardioembolic ischemic stroke 
or TIA. Furthermore, we were able to assess potential hetero-
geneous treatment effects among different subgroups. We did 
an IPD-NMA to combine the evidence from all relevant (di-
rect and indirect) treatment comparisons into one single anal-
ysis, while fully preserving randomization. Although NMA 
has been criticized, results from conventional random-effects 
meta-analyses of direct within-trial comparisons were con-
cordant with results from our IPD-NMA.
Our meta-analysis had some limitations. Although the 
sample size was large, the ability to provide adjusted treat-
ment effect estimates for all subgroups analyzed was limited 
by the number of patients in each subgroup. Second, too few 
studies were available to be able to study between-trial heter-
ogeneity. Third, we compared treatments for several relevant 
clinical outcomes and subgroups. Given the strong, predefined 
rationale (see published protocol15), we did not explicitly ad-
just for multiple comparisons. Fourth, trial populations were 
similar in many respects, but they varied in some entry criteria. 
These differences, however, allowed us to explore and con-
firm a consistent benefit across wide ranges of age, qualifying 
diagnoses, and additional patient characteristics. The consist-
ency of results across all 6 trials suggests that our findings are 
generalizable to a broad range of patients with noncardioem-
bolic ischemic stroke or TIA. Fifth, most patients in the sec-
ondary stroke prevention trials were already beyond the very 
early high-risk period after their initial TIA or stroke when 
recruited. We found no evidence for differences in treatment 
effects in patients randomized in the subacute and late phases, 
but acute effects might differ. The results of the POINT and 
CHANCE trial suggest that the aspirin/clopidogrel combina-
tion is beneficial over aspirin alone when initiated early after 
stroke and continued for about 3 weeks.31,32
Our findings raise questions about the mechanisms by 
which clopidogrel and aspirin/dipyridamole combination cause 
major bleeding. CYP2C19 genetic variants decrease the effi-
cacy of clopidogrel, but no association between bleeding risk 
and carrier status is observed yet.31,33,34 It is therefore not clear 
if CYP2C19 genetic variants influence the risk of bleeding.
Hence, both clopidogrel and aspirin/dipyridamole com-
bination can be used in the long-term secondary prevention 
of noncardioembolic stroke or TIA. The aspirin/clopidogrel 
combination significantly increases the risk of major bleeding 
compared with other antiplatelet regimens. Given the similar 
net clinical benefit outcome of clopidogrel and aspirin/dipyr-
idamole combination, selection of antiplatelet therapy for the 
secondary prevention of stroke must be individualized accord-
ing to patient needs, bleeding risks, and costs.
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